VentiRx shutters San Diego office; Acceleron nabs $7.5M milestone; Merck Serono finds a home for China R&D;

@FierceBiotech: Patch works as a method to deliver fenretinide to the mouth for oral cancers. Item The patch is applied to the inner cheek. | Follow @FierceBiotech

@JohnCFierce: Details on our Boston breakfast with Vertex's Peter Mueller, Biogen's Doug Williams, Omid Farokhzad and Steven Knight. More | Follow @JohnCFierce

@RyanMFierce: My quick take on Vertex CEO's tiff with analyst: Sounds brave but not sure if it's in the best interest of $VRTX shareholders. We'll see... | Follow @RyanMFierce

@MaureenFierce: Researchers have developed a self-propelled micromotor which could one day swim through a patient's blood stream, repairing the body. Story | Follow @MaureenFierce

> VentiRx tells Xconomy that it has decided to shutter its office in San Diego and concentrate all its resources in Seattle, where the biotech has been doing its cancer research. Co-founder Mike Kamdar has resigned as CBO and Rob Hershberg is handling the day-to-day operations. Story

> Acceleron has picked up a $7.5 million milestone from Celgene after launching an early-stage on an experimental anemia treatment partnered with Celgene. Article

> The CRO Pharmaron says its new campus in the Beijing Economic and Technological Development Area will serve as home to Merck Serono's China R&D Laboratory. Pharmaron release

> Jessica Federer of Bayer HealthCare Pharmaceuticals says the cost of doing research on Alzheimer's treatments is so high it's discouraging developers from working in the field. And maybe a new approach to R&D is needed she says. Report

> Following a September, 2009 conviction for wire fraud, former InterMune CEO Scott Harkonen has been barred from participating in anything involving Medicare and Medicaid. Item

> Aeterna Zentaris says it has gathered positive data from a mid-stage study of a new treatment for advanced endometrial cancer. Release

> Cellzome has hit more, undisclosed, milestones in its pact with GlaxoSmithKline. Story

Pharma News

@FiercePharma: Barclays downgrades Pfizer, cuts target to $19: Not impressed enough with near-term pipeline. News | Follow @FiercePharma

> Aspen Pharmacare eyes another $800M in M&A. Report

> Feds to reply in Purdue execs' exclusion appeal. More

> Pfizer delaying nutritionals sale to weigh tax hit. Article

> Healthcare's budget plan leans on Medicare beneficiaries. Piece

Medical Device News

> Boston Sci snags J&J exec as next CEO. News

> Intersect ENT sees positive data on Propel from pivotal trial. Article

> Zimmer gets pediatric clearance for spinal fixation system. Piece

> RF Surgical closes $12M round. More

> Keltjens tapped as Endosense president, CEO. Story

> Miracor raises $10M in Series B. News

Drug Delivery News

> Adenosine used to break through BBB, deliver large-molecule drugs. Report

> Patch works as delivery method for oral cancer. Article

> Nasal delivery of insulin appears to help Alzheimer's patients. Story

> Marina Biotech pins new hopes on patents for RNAi revival. Piece

> 'Trojan Horse' sneaks into cells using tumor's own defense mechanism. Item

> Smuggling drugs across the blood-brain barrier. Story

And Finally... Scientists in the U.K. are laying the groundwork for a large clinical trial to determine if a simple vitamin B supplement can ward off Alzheimer's. Report

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.